Abstract
Transplantation of embryonic nigral grafts into the striatum of Parkinson's disease patients is not optimal, mainly due to low survival of grafted neurones. Current strategies focus on enhancing neuronal survival by transplanting enriched neuronal cell populations. There is growing evidence for the importance of astroglia in neuronal survival.To characterise the effects of glial cells on dopaminergic neurones, 5-fluoro-2′-deoxyuridine was added to embryonic rat ventral mesencephalic cultures in the presence or absence of serum. The survival and morphology of glial fibrillary acidic protein immunopositive astroglia and tyrosine hydroxylase immunopositive dopaminergic neurones was examined. In serum-containing medium, astroglial cells predominated and 5-fluoro-2′-deoxyuridine had no significant effect on either astroglia or dopaminergic neurone survival.
In serum-free medium, astroglial growth was attenuated and numbers were significantly lower in 5-fluoro-2′-deoxyuridine treated compared with untreated cultures. There was no significant difference in the numbers of dopaminergic neurones between 5-fluoro-2′-deoxyuridine treated and untreated cultures. However, by the eighth day in vitro, there were differences in the morphology of these neurones between treated and untreated cultures. This study shows that the use of 5-fluoro-2′-deoxyuridine and serum-free medium can produce a neurone-enriched culture. However, the dopaminergic neurone population present in these cultures appeared to be morphologically dissimilar to those found in control cultures as neurites were retracted and the cell somas of these cells appeared enlarged. These results provide information on the effects of astrocytes on dopaminergic neurones in ventral mesencephalic cultures and thus have implications for transplantation in Parkinson's disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
AHLSKOG, J. E. (1993) Cerebral transplantation for Parkinson's disease: Current progress and future prospects. Mayo Clinic Proceedings 68, 578–591.
ALEXI, T., BORLONGON, C. V., FAULL, R. L. M., WILLIAMS, C. E., CLARK, R. G., GLUCKMAN, P. D. & HUGHES, P. E. (2000) Neuroprotective strategies for basal ganglia degeneration: Parkinson's and Huntington's diseases. Progress in Neurobiology 60, 409–470.
BARKER, R. & JOHNSON A. (1995) Nigral and striatal neurons. In Neural Cell Culture (edited by COHEN J. & WILKIN G. P.) pp. 25–39. Oxford University Press.
BJÖRKLUND, A. (1992) Dopaminergic transplants in experimental parkinsonism: Cellular mechanisms of graft induced functional recovery. Current Opinion in Neurobiology 2, 683–689.
BJÖRKLUND, A. & STENEVI, U. (1979) Reconstruction of the nigrostriatal dopamine pathway by intracerebral implants. Brain Research 177, 555–560.
BRANTON, R. L. & CLARKE, D. J. (1999) Apoptosis in primary cultures of E14 rat ventral mesencephala, time course of dopaminergic cell death and implications for neural transplantation. Experimental Neurology 160, 88–98.
BRUNDIN, P., KARLSSON, J., EMGÅRD, M., KAMINKI SCHIERLE, G. S., HANSSON, O., PETERSÉN, Å. & CASTILHO, R. F. (2000) Cell Transplantation 9, 179–195.
BRUNDIN, P., STREKER, R., WIDNER, H., CLARKE, D., NILSSON, O., LINDVALL, O. & BJÖRKLUND, A. (1998) Human fetal dopamine neurons grafted in a rat model of Parkinson's disease: Immunological aspects, spontaneous and drug-induced behaviour and dopamine release. Experimental Brain Research 70, 192–208.
CLARKSON, E. D. & FREED, C. R. (1999) Development of fetal neural transplantation as a treatment for Parkinson's disease. Life Sciences 65, 2427–2437.
DAVIES, A. M., LARNET, Y., WRIGHT, E. & VOGAL, K. S. (1991) Coordination of neurotrophic interactions by separate developmental programs in sensory neurons and their target fields. Journal of Cell Science 100(Suppl 15), 111–116.
DUNNETT, S. B. & BJÖRKLUND, A. (1999) Prospects for new restorative and neuroprotective treatments in Parkinson's disease. Nature 399(Suppl), A32–A39.
ENGELE, J., SCHUBERT, D. & BOHN, M. C. (1991) Conditioned media derived from glial cell lines promote survival and differentiation of dopaminergic neurons in vitro: Role of mesencephalic glia. Journal of Neuroscience Research 30, 359–371.
HOFFER, B. J. & VAN HORNE, C. (1995) Survival of dopaminergic neurons in fetal-tissue grafts. New England Journal of Medicine 332, 1163–1164.
MARSDEN, C. D. (1994) Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry 57, 672–681.
MASUKO, S., NAKAJIMA, S. & NAKAJIMA, Y. (1992) Dissociated high-purity dopaminergic neuron cultures from the substantia nigra and the ventral tegmental area of the postnatal rat. Neuroscience 49, 347–364.
MENA, M. A., DE BERNARDO, S., CASAREJOS, M. J., CANALS, S. & RODRÍGUEZ-MARTIN, E. (2002) The role of astroglia on the survival of dopamine neurons. Molecular Neurobiology 25, 245–263.
MÑLLER, H. W., JUNGHANS, U. & KAPPLER, J. (1995) Astroglial neurotrophic and neurite-promoting factors. Pharmac Ther 65, 1–18.
O'MALLEY, E. K., SIEBER, B.-A., MORRISON, R. S., BLACK, I. B. & DREYFUS, C. F. (1994) Nigral type 1 astrocytes release a soluble factor that increases dopaminergic neuron survival through mechanisms distinct from fibroblast growth factor. Brain Research 647, 83–90.
PANCHISION, D. M., MARTIN-DELEON, P. A., TAKESHIMA, T., JOHNSTON, J. M., SHIMODA, K., TSOULFAS, P., MCKAY, R. D. G., COMMISSIONG, J. W. (1998) An immortalized, Type-1 astrocyte of mesencephalic origin source of a dopaminergic neurotrophic factor. Journal of Molecular Neuroscience 11, 209–221.
PERLOW, M. J., FREED, W. J., HOFFER, B. J., SEIGER, A., OLSON, L. & WYATT, R. J. (1979) Brain grafts reduce motor abnormalities produced by the destruction of nigrostriatal dopamine system. Science 204, 643–647.
SAWLE, G. V., BLOOMFIELD, P. M., BJÖRKLUND, A., BROOKS, D. J., BRUNDIN, P., LEENDERS, K. L., LINDVALL, O., MARSDEN, C. D., REHNCRONA, S., WIDNE, H. & FRACKOWIAK, R. S. G. (1992) Transplantation of fetal dopamine neurons in Parkinson's disease, PET-[18F]-6-L-Fluorodopa studies in 2 patients with putaminal implants. Annals of Neurology 31, 166–173.
SORTWELL, C. E., DALEY, B. F., PITZER, M. R., MCGUIRE, S. O., SLADEK, JR, J. R. & COLLIER, T. J. (2000) Oligodendrocyte-type 2 astrocyte derived trophic factors increase the survival of developing dopaminergic neurons through the inhibition of apoptotic cell death. Journal of Comparative Neurology 426, 143–153.
TAKESHIMA, T., JOHNSTON, J. M. & COMMISSIONG, J. W. (1994a) Oligodendrocyte-type-2 astrocyte (O-2A) progenitors increase the survival of rat mesencephalic dopaminergic neurons from death induced by serum deprivation. Neuroscience Letters 166, 178–182.
TAKESHIMA, T., SHIMODA, M., SAUVE, Y. & COMMISSIONG, J. W. (1994b) Astrocyte-dependent and independent phases of the development and survival of rat embryonic day 14 mesencephalic, dopaminergic neurons in culture. Neuroscience 60, 809–823.
TAKESHIMA, T., SHIMODA, M., SAUVE, Y. & COMMISSIONG, J. W. (1994c) Mesencephalic Type 1 astrocytes rescue dopaminergic neurons from death induced by serum deprivation. Journal of Neuroscience 14, 4769–4779.
THAJEB, P. (1999) Neurotrophic factors increase tyrosine hydroxylase immunoreactive cell density of fetal mesencephalic cells. Chinese Medical Journal 112, 49–52.
WIDNER, H., TETRUD, J., REHNCRONA, S., SNOW, B., BRUNDIN, P., GUSTAVII, B. & BJÖRKLUND, A. (1992) Bilateral fetal mesencephalic grafting in 2 patients with Parkinsonism induced by MPTP. New England Journal of Medicine 327, 1556–1563.
YUREK, D. M. & SLADEK, JR, J. R. (1990) Dopamine cell replacement, Parkinson's disease. Annual Review of Neuroscience 13, 415–440.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wood, T.K., Sullivan, A.M. & McDermott, K.W. Viability of dopaminergic neurones is influenced by serum and astroglial cells in vitro . J Neurocytol 32, 97–103 (2003). https://doi.org/10.1023/A:1027384416811
Issue Date:
DOI: https://doi.org/10.1023/A:1027384416811